CJC-1295 Half Life: Pharmacokinetics in the Published Research

CJC-1295 half life: 5.8 to 8.1 days for the DAC form

The CJC-1295 half life depends entirely on which form you mean. For the DAC (albumin-conjugated) form, the estimated half-life is 5.8 to 8.1 days in healthy adults ^[1]. That is the number that defines the compound's reputation — a peptide that, once dosed, keeps acting for the better part of a week.

The downstream signal lasts even longer than the parent. After single subcutaneous doses of 30 or 60 micrograms per kilogram, mean plasma growth hormone rose 2- to 10-fold for six days or more and IGF-1 rose 1.5- to 3-fold for nine to eleven days; after multiple doses, IGF-1 remained above baseline for up to 28 days ^[1]. The pharmacokinetic curve does not spike and crash — it rises and holds, which is the practical meaning of a multi-day half-life carried by serum albumin.

Why the half-life is so long: the albumin bond

The mechanism behind the long half-life is bioconjugation to serum albumin. Native GHRH(1-29) is degraded in plasma within minutes, chiefly by DPP-IV and trypsin-like enzymes ^[11], and early work confirmed that short native half-life in healthy men ^[12]. CJC-1295's four substitutions slow enzymatic breakdown, but the decisive step is the DAC linker, which forms a covalent bond to circulating albumin so the peptide inherits albumin's long residence time ^[2].

The rat data illustrate the durability directly: the albumin-conjugate was detectable in plasma beyond 72 hours and produced a 4-fold increase in growth-hormone exposure over two hours versus the unconjugated peptide ^[2]. PEGylation was explored as an alternative half-life-extension route for GHRH analogs ^[3], underscoring that the long-acting problem was a known medicinal-chemistry challenge — and that albumin conjugation was CJC-1295's particular answer to it.

The no-DAC half-life is short

The no-DAC form — Modified GRF (1-29) — has a short half-life, in the minutes-to-hours range, reflecting native GHRH(1-29) clearance modified only by the protease-resistant substitutions. Without the albumin bond there is nothing to extend its circulation, so it produces a brief growth-hormone pulse rather than the sustained, days-long elevation of the DAC form. Confusing the two half-lives is the most common pharmacokinetic error in the popular discussion of this peptide; the difference is roughly a factor of hundreds.

Once-daily was enough in the model that tested it

An animal study put the long-acting schedule to a functional test. In GHRH-knockout mice, 2 micrograms of CJC-1295 given once every 24 hours fully normalized body weight and length, while dosing every 48 to 72 hours was progressively less effective; treatment also raised pituitary growth-hormone messenger RNA ^[4]. The takeaway is mechanistic, not a human regimen: the long-acting analog's duration was sufficient that once-daily dosing restored GH-axis-dependent growth, where less frequent dosing fell short.

The downstream signal outlasts the peptide

A half-life describes the parent molecule, but the biologically interesting duration is the signal it leaves behind. CJC-1295's downstream effects run longer than its 5.8-to-8.1-day half-life would suggest on its own, because the GH/IGF-1 axis has its own kinetics layered on top.

The human data make this concrete. Growth hormone rose 2- to 10-fold for six days or more after a single dose, IGF-1 rose 1.5- to 3-fold for nine to eleven days, and after repeated dosing IGF-1 stayed elevated above baseline for up to 28 days ^[1]. In a separate cohort of healthy men, basal growth hormone was still roughly 7.5-fold elevated and mean growth hormone about 46% above baseline a full week after a single dose ^[3]. So the practical 'duration of effect' is governed by two clocks at once: the albumin-bound peptide's slow clearance, and the slower turnover of IGF-1 it drives. That layering is why a single administration produces a sustained plateau rather than a transient bump.

Native GHRH versus the analog: a clarifying contrast

The half-life story lands hardest when you set the analog against the molecule it copies. Native human GHRH(1-29) survives in plasma for only minutes, cleared chiefly by DPP-IV and trypsin-like enzymes ^[11]. That fragility is intrinsic to the natural signal — the body's own GHRH is meant to fire in brief bursts.

CJC-1295's engineering reverses that. The four substitutions slow enzymatic clearance, and the DAC albumin bond carries the peptide for days ^[2], so the same receptor sees a steady signal where it would normally see a flicker. The animal data put a number on the gap: the albumin-conjugate was still detectable beyond 72 hours and produced a 4-fold increase in growth-hormone exposure over two hours versus the unconjugated peptide ^[2]. Read together, the contrast explains the whole point of the molecule — it is a long-acting answer to a short-acting natural signal, and the half-life is the headline of that answer.

What a multi-day half-life does and does not imply

A long half-life is a pharmacokinetic fact, not a safety endorsement. What it does imply is that the GH/IGF-1 elevation from the DAC form is sustained and not easily reversed once dosed — the signal cannot simply be switched off, because the peptide rides albumin's days-long circulation. That same property is the reason the safety questions around chronic GH-axis stimulation are taken seriously: a sustained elevation is harder to titrate and longer to clear than a short pulse.

What the long half-life does not imply is that any particular dosing schedule is established or safe in humans. There is no approved human dose, the long-acting DAC development program was discontinued, and the duration figures here come from short-term pharmacokinetic studies, not long-term use. The half-life tells you how the molecule behaves in the bloodstream; it tells you nothing about whether sustained GH/IGF-1 elevation is wise to pursue, which is a separate question the literature has not answered for CJC-1295.